Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company's product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. The Company's product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: OTIC
- Previous Close: $14.95
- 50 Day Moving Average: $15.40
- 200 Day Moving Average: $16.52
- 52-Week Range: $10.50 - $19.38
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.49
- P/E Growth: -0.20
- Market Cap: $451.40M
- Outstanding Shares: 30,194,000
- Beta: 2.91
- Return on Equity: -46.65%
- Return on Assets: -44.40%
Companies Related to Otonomy:
- Current Ratio: 17.58%
- Quick Ratio: 17.44%
What is Otonomy's stock symbol?
Otonomy trades on the NASDAQ under the ticker symbol "OTIC."
Where is Otonomy's stock going? Where will Otonomy's stock price be in 2017?
2 brokerages have issued 1 year price targets for Otonomy's stock. Their predictions range from $29.00 to $32.00. On average, they anticipate Otonomy's share price to reach $30.50 in the next twelve months.
When will Otonomy announce their earnings?
Otonomy is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
Who owns Otonomy stock?
Otonomy's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Federated Investors Inc. PA (9.73%), Orbimed Advisors LLC (6.13%), FMR LLC (2.42%), Kingdon Capital Management L.L.C. (2.00%), State Street Corp (1.74%) and Clough Capital Partners L P (0.78%). Company insiders that own Otonomy stock include Carl Lebel, Chau Quang Khuong, David Allen Weber, Orbimed Advisors Llc, Paul E Cayer and Robert Michael Savel II.
Who sold Otonomy stock? Who is selling Otonomy stock?
Otonomy's stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Federated Investors Inc. PA, FT Options LLC and Clough Capital Partners L P.
Who bought Otonomy stock? Who is buying Otonomy stock?
Otonomy's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Dimensional Fund Advisors LP, Kingdon Capital Management L.L.C., Flinton Capital Management LLC, Tyers Asset Management LLC, Russell Investments Group Ltd. and FIL Ltd.
How do I buy Otonomy stock?
Shares of Otonomy can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Otonomy stock cost?
One share of Otonomy stock can currently be purchased for approximately $14.95.